Copenhagen 2016 Registration Programme Exhibitor Information Virtual Exhibition Satellite Meetings Glaucoma Day 2016 Hotel Star Alliance
title

10 - 14 Sept. 2016, Bella Center, Copenhagen, Denmark

This Meeting has been awarded 27 CME credits

 

escrs app advert yo advert

Four-year results of riboflavin ultraviolet-A corneal collagen cross-linking for progressive corneal ectasia in 129 eyes

Search Title by author or title

Session Details

Session Title: Presented Poster Session: Cross-linking

Session Date/Time: Sunday 11/09/2016 | 09:30-11:00

Paper Time: 09:30

Venue: Poster Village: Pod 3

First Author: : S.AL Zaid SAUDI ARABIA

Co Author(s): :    S. Al Swailem              

Abstract Details

Purpose:

To report the clinical course of conventional corneal collagen cross-linking (CXL) with up to 4.7 years of follow-up, for the treatment of progressive corneal ectasia.

Setting:

Anterior segment division, King Khalid eye Specialist Hospital, Saudi Arabia.

Methods:

The records of 129 eyes (keratoconus = 114; post-excimer ectasia=15) which underwent CXL using Dresden’s protocol, were reviewed retrospectively. At the baseline and all follow-up examinations, Snellen uncorrected visual acuity (UCVA), Snellen best corrected visual acuity (BCVA), simulated mean keratometry(Sim K) reading, central corneal thickness (CCT), and complications were analysed.

Results:

The mean age of the 83 men and 46 women was 24.73± 5.5 (range 14-42) years, and 68.2% were in the age range of 21-30 years. The CCT almost resumed its baseline reading at 9-months postoperatively (460.5 vs. 479.7um), and stabilized thereafter (465.3um) (p<0.086). At last follow-up, median Sim K decreased from 45.1±3.6D (range 37.9-66.9D) to 44.5±3.6D(range 37.6-60.5D) (p<0.008). At last follow-up, median UCVA and BCVA changed from 20/60 to 20/40 and 20/25 to 20/25, respectively. The UCVA of ≥20/40 was recorded in 38.8% and 53.3% before and after CXL, respectively. At last follow-up, mean UCVA improved and worsened by ≥ 1 Snellen line in 27.1% and 10.8%, respectively. Complications included: transient corneal haze(n=9) and sterile infiltrate(n=3).

Conclusions:

Our study not only demonstrated a halt in ectasia progression, but also showed a significant improvement in visual acuity at 4-year of follow-up. Conventional CXL is safe in stabilization of progressive ectasia. Given the simplicities, minimal costs of CXL and likelihood of reducing the need of keratoplasty, it might also be well-suited for developing countries.

Financial Disclosure:

NONE

Back to previous